Rep. Jake Auchincloss

Maddy summaryThis concurrent resolution directs the President to withdraw United States Armed Forces from any hostilities against Iran. It specifically invokes the War Powers Resolution, mandating this removal unless Congress formally declares war or provides specific authorization for military force against Iran. The bill clarifies that it does not prevent the U.S. from acting in self-defense, maintaining a defensive troop presence in the region, or continuing intelligence activities related to threats from Iran.

Maddy summaryThis concurrent resolution directs the President to withdraw U.S. military forces from hostilities with Iran. It invokes Section 5(c) of the War Powers Resolution, which allows Congress to end ongoing military engagements. The bill permits keeping troops only if they are needed to defend the U.S. or its allies from an immediate attack, provided the President follows specific reporting rules. All other forces must be removed unless Congress has passed a formal declaration of war or a specific authorization for using military force against Iran.

Maddy summaryThis bill would require Medicare to cover early detection screening tests for Alzheimer's disease and related dementias starting January 1, 2028. It defines eligible tests as FDA-cleared genomic blood tests, blood product analyses, or equivalent medical imaging methods (like protein expression or whole genome sequencing) that detect pre-symptomatic or early-stage conditions. Medicare beneficiaries would receive this coverage without cost-sharing for these specific screenings. The bill amends Medicare coverage rules to explicitly include these tests under Section 1861(nnn) of the Social Security Act.

Maddy summaryHR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.

Maddy summaryThis bill requires all new passenger vehicles manufactured for sale in the U.S. to include AM radio as standard equipment (not an optional add-on) by 2027-2028, depending on manufacturer size. It mandates that AM radio receivers must be easily accessible to drivers and allows compliance through digital AM broadcast technology. During a transition period, manufacturers must clearly label vehicles without AM radio but cannot charge extra for this feature. The bill also mandates a GAO study on AM radio's role in emergency alerts and includes a 10-year sunset provision for the rule. It preempts state laws regarding AM radio access in vehicles.

Maddy summaryThe Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 requires Medicare Part D and Advantage plans to use a standardized public bidding process for pharmacy benefit managers starting in 2028, ensuring that the lowest projected net effective cost is generally selected. The bill mandates that plan sponsors maintain real-time tools to track actual drug costs and escrow funds to refund enrollees if they are overcharged relative to their bids. It also establishes a new five-star rating system for these plans based on how closely actual spending matches projections, with low-performing plans required to notify beneficiaries of alternative options. Additionally, the legislation extends similar transparency requirements to commercial health plans by requiring them to disclose projected net effective costs in their bid submissions.

Maddy summaryThe Priority for Pediatric Cures Act permanently extends the authority to award priority review vouchers for drugs and biologics that treat rare pediatric diseases. By amending the Federal Food, Drug, and Cosmetic Act, the bill removes a specific expiration provision that would otherwise limit this incentive program. This change ensures that pharmaceutical companies can continue to receive expedited FDA review in exchange for developing treatments for children with rare conditions.

Maddy summaryThe CCP Fentanyl Sanctions Act codifies existing executive sanctions and authorizes the President to impose new financial penalties on foreign persons, including Chinese government entities, ports, online marketplaces, and companies that contribute to the global spread of illicit synthetic narcotics. The bill targets specific activities such as producing or selling precursor chemicals, facilitating drug shipments, and providing material support to sanctioned government bodies, with the primary penalty being the blocking of all property and transactions within the United States. Additionally, the Treasury Department is empowered to restrict access to U.S. banking accounts for foreign financial institutions that knowingly facilitate significant transactions for these designated individuals or entities. The legislation includes provisions allowing the President to waive sanctions for up to 180 days if deemed in the national interest and requires the administration to consider information from congressional committees and international human rights monitors when making determinations.